מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)
TYA Pharmaceuticals
LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM ANHYDROUS 50 ug
ORAL
PRESCRIPTION DRUG
Levothyroxine sodium is used for the following indications: – As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Hypothyroidism – In the treatment or prevention of various types of euthyroid goiters (see and ), including thyroid nodules (see and ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see and ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
NDC:64725-5181-1 in a BOTTLE of 100 TABLETS
New Drug Application
LEVOTHYROXINE SODIUM- LEVOTHYROXINE SODIUM TABLET TYA PHARMACEUTICALS ---------- LEVOTHYROXINE SODIUM TABLETS, USP DESCRIPTION Levothyroxine sodium tablets, USP contains synthetic crystalline L-3,3’,5,5’-tetraiodothyronine sodium salt [levothyroxine (T ) sodium]. Synthetic T is identical to that produced in the human thyroid gland. Levothyroxine (T ) sodium has an empirical formula of C H I N NaO x H O, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown: INACTIVE INGREDIENTS Magnesium Stearate, NF; Microcrystalline Cellulose, NF; Colloidal Silicone Dioxide, NF; Sodium Starch Glycolate, NF. The following are the color additives by tablet strength: STRENGTH (MCG) COLOR ADDITIVE(S) 25 FD&C Yellow No. 6 Aluminum Lake 50 None 75 FD&C Blue No. 2 Aluminum Lake D&C Red No. 27 Aluminum Lake 88 FD&C Blue No. 1 Aluminum Lake D&C Yellow No. 10 Aluminum Lake D&C Red No. 30 Aluminum Lake 100 D&C Yellow No. 10 Aluminum Lake D&C Red Lake Blend (D&C Red No. 27 Lake and D&C Red No. 30 Lake) 112 D&C Red No. 27 Aluminum Lake D&C Red No. 30 Aluminum Lake 125 FD&C Yellow No. 6 Aluminum Lake FD&C Red No. 40 Aluminum Lake FD&C Blue No. 1 Aluminum Lake 137 FD&C Blue No. 1 Aluminum Lake 150 FD&C Blue No. 2 Aluminum Lake 175 D&C Red No. 27 Aluminum Lake D&C Red No. 30 Aluminum Lake FD&C Blue No. 1 Aluminum Lake 200 D&C Yellow No. 10 Aluminum Lake D&C Red No. 27 Aluminum Lake 300 D&C Yellow No. 10 Aluminum Lake FD&C Yellow No. 6 Aluminum Lake FD&C Blue No. 1 Aluminum Lake CLINICAL PHARMACOLOGY Thyroid hormone synthesis and secretion is regulated by the hypothalamic-pituitary-thyroid axis. Thyrotropin-releasing hormone (TRH) released from the hypothalamus stimulates secretion of 44 41510442 thyrotropin-stimulating hormone, TSH, from the anterior pituitary. TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, L-thyroxine (T ) and L-triiodothyronine (T ), by the thyroid gland. Circulating serum T and T levels exert a feedback effect on both TRH and TSH secretion. When ser קרא את המסמך השלם